Charles Ericsson, MD
Infectious Disease · Houston, TXNPI 1477571941
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,500 of the $5,690 with a category attached, or 61.5%. Redhill Biopharma Inc. accounts for 61.5% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2020 at $3,826 and has fallen 96.8% since, to $121 in 2021.
Across 123 payments — averaging $46.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Redhill Biopharma Inc.$4K
- Melinta Therapeutics, LLC$568
- Merck$424
- Insmed, Inc.$290
- Tetraphase Pharmaceuticals, Inc.$276
- Paratek Pharmaceuticals, Inc.$199
- plus $434 from 6 others
What the payments were for
- Consulting fees$3,50062%
- Food & beverage$2,17838%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Redhill Biopharma Inc. | 1 | $3,500 |
| Melinta Therapeutics, LLC | 29 | $568 |
| Merck | 31 | $424 |
| Insmed, Inc. | 11 | $290 |
| Tetraphase Pharmaceuticals, Inc. | 11 | $276 |
| Paratek Pharmaceuticals, Inc. | 11 | $199 |
| Astellas Pharma US Inc | 8 | $185 |
| AbbVie(2 entities) | 16 | $146 |
| Stryker | 1 | $45 |
| Pfizer | 2 | $28 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| Shionogi Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,690 in reported general payments places this provider in the 80th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl | 20 | $1,383 |
| Azithromycin | 43 | $534 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 30 | $526 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Houston
- Joseph GatheHouston$695K
- Roy ChemalyHouston$686K
- Ben BarnettHouston$424K
- Amar SafdarHouston$284K
- Luis OstroskyHouston$173K
- Richard HamillHouston$137K
- Karen VigilHouston$91K
- John RexHouston$63K
- Pablo OkhuysenHouston$57K
- Rodrigo HasbunHouston$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.